Healing & RecoveryLimited ResearchInvestigationalD

Larazotide

AT-1001

Last reviewed . First published . By the PeptIQ team.

Educational and observational reference only. Not medical advice. Community charts may use modeled aggregates when live snapshots are unavailable.

Studies cited
4
Research grade
D
Experience
68

Overall check-ins

Activity
49

Trackers & reports

Typical Dose

Varies by protocol

Route

Oral

Cycle

Trial protocol-dependent

Storage

Room Temperature

What is Larazotide?

Tight-junction regulator peptide studied for gut barrier and celiac-associated symptoms.

Research Indications

Tissue RepairMost Effective

Demonstrated acceleration of wound healing and soft tissue repair in research

Gut HealthEffective

Research shows beneficial effects on intestinal lining and GI function

Joint SupportEffective

Associated with reduced joint inflammation and improved mobility

Muscle RecoveryModerate

May support faster recovery from muscle strains and exercise stress

Research Protocols

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

GoalDoseFrequencyRoute
Starting Dose100 mcgOnce dailySubcutaneous injection
Standard Dose250 mcgOnce dailySubcutaneous injection

Peptide & Drug Interactions

Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.

TB-500 / BPC-157 (stack)Compatible
NSAIDs (Ibuprofen, Naproxen)Caution
CorticosteroidsCaution
AnticoagulantsMonitor
GH SecretagoguesCompatible
NAD+Compatible

How to Reconstitute & Inject

Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.

  1. 1

    Remove Larazotide vial from refrigeration and allow to reach room temperature (15–20 minutes)

  2. 2

    Clean vial top with alcohol swab and allow to air dry completely

  3. 3

    Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)

  4. 4

    Inject BAC water slowly down the side of the vial — do not aim directly at the powder

  5. 5

    Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide

  6. 6

    Allow 2–3 minutes for full dissolution — solution should be clear and colorless

  7. 7

    Draw calculated dose into an insulin syringe for subcutaneous injection

  8. 8

    Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy

  9. 9

    Store reconstituted solution refrigerated (2–8°C) and use within 28 days

What to Expect

Week 1–2

Initial anti-inflammatory effects begin. Reduced pain and swelling in target area.

Week 2–4

Improved tissue mobility and reduced discomfort. Early healing acceleration.

Week 4–8

Significant recovery milestones. Stronger tissue repair and functional improvement.

Week 8–12

Near-complete healing in many cases. Improved strength and tissue integrity.

Side Effects & Safety

  • Generally well-tolerated in research settings
  • Mild nausea with higher doses
  • Injection site redness or discomfort
  • Rare: Dizziness or lightheadedness
  • Potential effect on blood pressure (monitor if hypertensive)

FDA Status & Regulatory Info

Investigational

Tight-junction regulator peptide studied for gut barrier and celiac-associated symptoms.

Rx Required: No
503A Ban: No
Telehealth: N/A
Full FDA Status Tracker

Frequently Asked Questions

Community-reported data

The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.

What 1,343 users report

Observational self-reports (modeled when live data is unavailable). Not clinical outcomes.

1343 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 47% · Mixed 34% · Unfavorable overall 19%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Energy
-14
Mood
-82
Focus
-135
Sleep quality
-142
Lean mass
-143

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Dizziness
-98
Fatigue
-2
Nausea
10
Water retention
-146
Appetite loss
-143

Self-reported dose per injection

Median bucket: 1–2 mg · Most common: 0.6–1 mg

Reports span 0.1 to ≥ 5 mg (open-ended top bucket)

0.1–0.2 mg
5
0.2–0.4 mg
15
0.4–0.6 mg
19
0.6–1 mg
29
1–2 mg
24
2–3 mg
13
3–5 mg
9
5+ mg
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing27stacking10side effects13larazotide26

How repeat users are trending

Among repeat reporters, 57% said they felt similar to their last entry, 45% more positive, and 17% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 28 days · Based on 295 repeat reporters

Share Your Experience

Rate Larazotide in the PeptIQ app and help the community make informed decisions.

Research References (3)

Cited PubMed, trial registry, and label sources for education only. We do not control third-party content.

  1. PubMed

    Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet

    Leffler DA, Kelly CP, Abdallah HZ, et al. Gastroenterology. 2015

    Source
    Wiki study page →
  2. PubMed

    Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration

    Damianos JA, Bledsoe A, Camilleri M, et al. Gut. 2026

    Source
    Wiki study page →
  3. PubMed

    The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate

    Khaleghi S, Ju JM, Lamba A, et al. Therapeutic advances in gastroenterology. 2016

    Source
    Wiki study page →

Wiki tools

Observational indexes and compare views for Larazotide.

Educational information only

This page is for educational reference. It is not medical or legal advice. PeptIQ does not sell peptides or list vendors. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.

PeptIQ app

Log your Larazotide protocol in PeptIQ

Turn this Larazotide guide into a living protocol — doses, vials, and history in one place.

Track LarazotideOpen web app

iOS, Android, and web

Ask PeptIQ

Two taps on our guided quiz, then keep going in iMessage with sources — not Instagram screenshots.

Start the quizOr try Peptide X Quiz →

Quick Facts

Route
Oral
Availability
Varies
Rx Required
No
503A Ban
No
Browse peptide education

Talk with a clinician

PeptIQ is education only. We do not sell peptides or list vendors. Discuss Larazotide with a licensed healthcare provider — not medical advice, not a prescription.

Download PeptIQ

Wiki tools

Observational indexes and compare views for Larazotide.